Fulminant Hepatic Failure after Chemosaturation with Percutaneous Hepatic Perfusion and Nivolumab in a Patient with Metastatic Uveal Melanoma

Figure 1

Liver function tests before, during, and after 2 cycles of nivolumab. The dates are numbered starting with the first day of the first cycle of nivolumab. AST: aspartate aminotransferase; ALT: alanine aminotransferase; day 1: start of the 1^st cycle of nivolumab; day 14: start of the 2^nd cycle of nivolumab; day 22: 1^st dose of corticosteroids. The graph shows the rapid increase in liver function tests after the patient began taking nivolumab and the minor response after being treated with corticosteroids. It also depicts the timeline until the patient perspired.